Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive

Maintenance: Tuesday, July the 26th 2016, 07:00-10:00

ZORA's new graphical user interface will be relaunched (For further infos watch out slideshow ZORA: Neues Look & Feel). There will be short interrupts on ZORA Service between 07:00am and 10:00 am. Please be patient.

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-14534

Senti, G; Prinz Vavricka, B M; Erdmann, I; Diaz, M I; Markus, R; McCormack, S J; Simard, J J; Wüthrich, B; Crameri, R; Graf, N; Johansen, P; Kündig, T M (2008). Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 105(46):17908-17912.

Accepted Version
View at publisher
[img] PDF - Registered users only


The only causative treatment for IgE-mediated allergies is allergen-specific immunotherapy. However, fewer than 5% of allergy patients receive immunotherapy because of its long duration and risk of allergic side effects. We aimed at enhancing s.c. immunotherapy by direct administration of allergen into s.c. lymph nodes. The objective was to evaluate safety and efficacy compared with conventional s.c. immunotherapy. In a monocentric open-label trial, 165 patients with grass pollen-induced rhinoconjunctivitis were randomized to receive either 54 s.c. injections with pollen extract over 3 years [cumulative allergen dose 4,031,540 standardized quality units (SQ-U)] or 3 intralymphatic injections over 2 months (cumulative allergen dose 3,000 SQ-U). Patients were evaluated after 4 months, 1 year, and 3 years by nasal provocation, skin prick testing, IgE measurements, and symptom scores. Three low-dose intralymphatic allergen administrations increased tolerance to nasal provocation with pollen already within 4 months (P < 0.001). Tolerance was long lasting and equivalent to that achievable after standard s.c. immunotherapy (P = 0.291 after 3 years). Intralymphatic immunotherapy ameliorated hay fever symptoms (P < 0.001), reduced skin prick test reactivity (P < 0.001), decreased specific serum IgE (P < 0.001), caused fewer adverse events than s.c. immunotherapy (P = 0.001), enhanced compliance (P < 0.001), and was less painful than venous puncture (P = 0.018). In conclusion, intralymphatic allergen administration enhanced safety and efficacy of immunotherapy and reduced treatment time from 3 years to 8 weeks.


133 citations in Web of Science®
155 citations in Scopus®
Google Scholar™



167 downloads since deposited on 26 Feb 2009
21 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
04 Faculty of Medicine > Center for Medical Research
Dewey Decimal Classification:570 Life sciences; biology
610 Medicine & health
Date:November 2008
Deposited On:26 Feb 2009 11:47
Last Modified:05 Apr 2016 13:03
Publisher:National Academy of Sciences
Additional Information:Copyright: National Academy of Sciences USA.
Publisher DOI:10.1073/pnas.0803725105
PubMed ID:19001265

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page